4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED

4BIO Capital Strengthens Investment Team

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly

4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences 

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer